



**Sino-American Pharmaceutical Professionals Association
Greater Philadelphia Chapter (SAPA-GP)**

Clinical Trials in New Drug Development Conference

8:30 AM – 5:30 PM, October 20 (Saturday) 2007

**Fort Washington Hotel & Conference Center (Holiday Inn)
432 Pennsylvania Ave, Fort Washington, PA 19034
(<http://www.fwholiday.com/>)**

Moderators – Tsang-Bin Tzeng (PhD, Senior Director, Clinical Pharmacology, AstraZeneca; EC of SAPA-GP and SAPA-HQ) and Li Yan (MD, PhD, Associate Director, Clinical Oncology, Merck; President-elected of SAPA-GP)

- 8:00** Refreshments
- 8:30** Welcome – Jian Li (PhD, Former President of SAPA-GP)
- 8:40** Introduction and Overview of Clinical Development – Tsang-Bin Tzeng (PhD, Senior Director, Clinical Pharmacology, AstraZeneca)
- 9:15** Phase I Clinical Trials – Zaiqi Wang (MD, PhD, Director, Early Clinical Research & Experimental Medicine, Schering-Plough Research)
- 9:50** Phase II Clinical Trials and the Challenges – Joan Shen (MD, PhD, Director, CNS, Clinical Research and Development, Wyeth Research)
- 10:25** Break
- 10:40** Pharmacokinetics and Pharmacodynamics – Bin Peng (MD, PhD, Director, Clinical Pharmacology and discovery Medicine Oncology, GlaxoSmithKline)
- 11:15** Interaction Studies with Food, Transporter Modifiers and Other Drugs – Charles Oo (PharmD, PhD, FCP, Director, Clinical Pharmacology, Asubi Pharmaceuticals)
- 11:50** Lunch
- 1:20** Phase III Clinical Trials and the Challenges – Jay Mei (MD, PhD, Director, Oncology Clinical Development, Novartis)

- 1:55** Statistical Considerations in Phase II /III Study Designs – Liannng Yuh (PhD, Vice President, Biometrics, Dendreon Corp.)
- 2:30** Translational Medicine and Biomarkers in Clinical Trials – Jingsong Wang (MD, Director, Clinical Discovery -Oncology/Immunology, Bristol-Myers Squibb)
- 3:05** Phase IV Trials and Life Cycle Management – David Liu (MD, PhD, Director, Therapeutic Specialist-Hematology/Oncology, Bristol-Myers Squibb)
- 3:40** Break
- 4:00** Pros and Cons of Conducting Clinical Trials in China – Dan Zhang (MD, PhD, CEO, Fountain Medical Development)
- 4:35** Beyond Risk/Benefit: Clinical Safety from Trial to Market – Ming Tong (MD, MBE, Medical Director, New York Headquarter, Pfizer)
- 5:00** Summary – Li Yan (MD, PhD, Associate Director, Clinical Oncology, Merck)
- 5:10** Speakers Roundtable Discussion – Questions & Answers
- 5:40** Adjourn